Chelation therapy was associated with lower rates of death, recurrent myocardial infarction and coronary revascularization in diabetes patients compared with placebo treatment, research presented at the American Heart Association meeting and published in Circulation: Cardiovascular and Quality Outcomes indicated. However, patients in the nondiabetes arm did not appear to benefit from the treatment, researchers said.

Related Summaries